Management of latent tuberculosis infection based on t-spot.tb assay in patients with hematological malignancies
Conclusions:INH treatment was generally well tolerated, and serious drug-related side effects were observed infrequently. Although LTBI cannot be demonstrated in patients with HIV(+) HM who are scheduled for chemotherapy, these patients should be closely monitored for the development of active TB infection.Keywords: Hematologic malignancies, Interferon-Gamma Release Assays, Latent tuberculosis
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Authors: Emrah Kiliacaslan, Kadir Canoglu Source Type: research
More News: Cancer & Oncology | Chemotherapy | Gastroenterology | Hematology | Infectious Diseases | Liver | Middle East Health | Study | Training | Tuberculosis | Turkey Health | Universities & Medical Training | Urology & Nephrology